During the past 40 years, the gap between rich and poor Americans has continued to widen in terms of health and mortality, as well as income.
PharmaKure granted MHRA Clinical Trial Authorisation (CTA) for PK051 for the treatment of mild cognitive impairment due to Alzheimer’s Disease
Clinical Trial Authorisation application granted for combined drug PK051 targeting amyloid deposits associated with Alzheimer’s Disease.
January 4, 2024